Inclusion Criteria:

          1. 18-75 years old ; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
             1; Life expectancy ≥ 3 months.

          2. Histologically or cytologically confirmed unresectable (Stage III) Non-Small Cell Lung
             Cancer.

          3. At least has one measurable lesion before radiotherapy.

          4. At least has one type of platinum-containing chemotherapy, Absence of progression
             after concurrent/sequential chemoradiotherapy.

          5. Adequate laboratory indicators.

          6. No pregnant or breastfeeding women, and a negative pregnancy test.

          7. Understood and signed an informed consent form.

        Exclusion Criteria:

          1. Squamous cell carcinoma meets following conditions should be excluded:

               1. Cavernous lung cancer.

               2. Has hemoptysis and maximum daily hemoptysis volume ≥ 2.5ml within 1 month before
                  the first administration.

          2. Has received anti-angiogenic drugs or other PD-1 / PD-L1 / CTLA-4 antibody therapy or
             other immunotherapy against PD-1 / PD-L1 / CTLA-4.

          3. Severe hypersensitivity occurs after administration of other monoclonal antibodies.

          4. Diagnosed and/or treated additional malignancy within 5 years with the exception of
             cured basal cell carcinoma of skin ,carcinoma in situ of prostate,and carcinoma in
             situ of cervix.

          5. Pathologically confirmed mixed small cell and non-small cell lung cancer.

          6. EGFR gene mutations.

          7. Has any active autoimmune disease or history of autoimmune disease.

          8. After the early stage of chemoradiotherapy, the treatment toxicity ≥ grade 2 is not
             fully alleviated.

          9. Has ≥grade 2 pneumonia.

         10. Immunosuppressant or systemic or absorbable local hormone therapy is required to
             achieve the aim of immunosuppression (dose > 10mg/ day prednisone or other
             therapeutic hormones) and is still used within 2 weeks after the first administration.

         11. Has multiple factors affecting oral medication.

         12. Has active bleeding or a persistent decrease in hemoglobin.

         13. Has any bleeding or bleeding events ≥grade 3 in the first 4 weeks before the first
             administration.

        2.Has received anti-angiogenic drugs or other PD-1 / PD-L1 / CTLA-4 antibody therapy or
        other immunotherapy against PD-1 / PD-L1 / CTLA-4.

        14. Has unhealed wounds, fractures, active gastric and duodenal ulcers, positive continuous
        fecal occult blood, ulcerative colitis in the first 4 weeks before the first
        administration.

        15. Has received NMPA approved anti-tumor drugs or immunomodulatory drugs for systemic
        treatment within 2 weeks before the first administration.

        16.Has a history of a hematological system transplantation or organ transplantation.

        17. Has active diverticulitis、peritoneal abscess, intestinal obstruction. 18. Has any
        serious and/or uncontrollable disease. 19. According to the judgement of the investigators,
        there are other factors that may lead to the termination of the study.